Roman Maslennikov
Overview
Explore the profile of Roman Maslennikov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gulyaeva K, Nadinskaia M, Maslennikov R, Aleshina Y, Goptar I, Lukashev A, et al.
Sci Rep
. 2025 Mar;
15(1):8394.
PMID: 40069378
Gut dysbiosis plays an important role in cirrhosis, but the mechanism of its development was not established. The aim of the study was to test the hypothesis that portal hypertension...
2.
Reshetova M, Markin P, Appolonova S, Yunusov I, Zolnikova O, Bueverova E, et al.
Biomolecules
. 2024 Nov;
14(11).
PMID: 39595625
The aim of this study was to investigate the levels of various tryptophan metabolites in patients with alcoholic liver disease (ALD) and metabolic-associated fatty liver disease (MAFLD) at different stages...
3.
Efremova I, Alieva A, Maslennikov R, Poluektova E, Zharkova M, Kudryavtseva A, et al.
Front Nutr
. 2024 Nov;
11:1438897.
PMID: 39539377
Background: Sarcopenia and gut dysbiosis are common in cirrhosis. The aim is to study the correlations between the gut microbiota taxa and muscle mass level in cirrhosis. Methods: The study...
4.
Maslennikov R, Benuni N, Levshina A, Adzhieva F, Demina T, Kucher A, et al.
Microorganisms
. 2024 Aug;
12(8).
PMID: 39203520
We aimed to systematize the results of published studies on the use of (SB) for the treatment of various liver disorders (CRD42022378050). Searches were conducted using PubMed and Scopus on...
5.
Efremova I, Maslennikov R, Kudryavtseva A, Avdeeva A, Krasnov G, Diatroptov M, et al.
J Clin Transl Hepatol
. 2024 Aug;
12(8):689-700.
PMID: 39130620
Background And Aims: Gut dysbiosis and abnormal cytokine profiles are common in cirrhosis. This study aimed to evaluate the correlations between them. Methods: In the blood plasma of cirrhosis patients...
6.
Ivashkin V, Maev I, Poluektova E, Sinitsa A, Avalueva E, Mnatsakanyan M, et al.
Clin Transl Gastroenterol
. 2024 Jul;
15(9):e1.
PMID: 39023173
Introduction: Increasing the effectiveness of eradication therapy is an important task in gastroenterology. The aim of this study was to evaluate the efficacy and safety of postbiotic containing inactivated (nonviable)...
7.
Efremova I, Maslennikov R, Poluektova E, Medvedev O, Kudryavtseva A, Krasnov G, et al.
World J Hepatol
. 2024 May;
16(5):822-831.
PMID: 38818295
Background: The gut-liver axis and bacterial translocation are important in cirrhosis, but there is no available universal biomarker of cellular bacterial translocation, for which presepsin may be a candidate. Aim:...
8.
Efremova I, Maslennikov R, Medvedev O, Kudryavtseva A, Avdeeva A, Krasnov G, et al.
Microorganisms
. 2024 Mar;
12(3).
PMID: 38543514
Gut dysbiosis and subclinical intestinal damage are common in cirrhosis. The aim of this study was to examine the association of intestinal damage biomarkers (diamine oxidase [DAO], claudin 3, and...
9.
Efremova I, Maslennikov R, Poluektova E, Medvedev O, Kudryavtseva A, Krasnov G, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38396668
Our aim was to study the association of endothelial dysfunction biomarkers with cirrhosis manifestations, bacterial translocation, and gut microbiota taxa. The fecal microbiome was assessed using 16S rRNA gene sequencing....
10.
Efremova I, Maslennikov R, Zharkova M, Poluektova E, Benuni N, Kotusov A, et al.
J Clin Med
. 2024 Feb;
13(3).
PMID: 38337613
(1) : The aim was to evaluate the effectiveness of the probiotic containing in the treatment of small intestinal bacterial overgrowth (SIBO) in patients with decompensated cirrhosis. (2) : This...